Generated by All in One SEO Pro v4.9.4, this is an llms.txt file, used by LLMs to index the site.

# Alessa Therapeutics

## Sitemaps

- [XML Sitemap](https://dev-alessa.pantheonsite.io/sitemap.xml): Contains all public & indexable URLs for this website.

## Posts

- [Hello world!](https://dev-alessa.pantheonsite.io/blog/hello-world/) - Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

## Pages

- [Home](https://dev-alessa.pantheonsite.io/) - Revolutionizing early-stage localized prostate cancer treatment. Each year, over a million men worldwide are diagnosed with localized prostate cancer with limited treatment options.
- [Science](https://dev-alessa.pantheonsite.io/science/) - Science Alessa Drug Delivery System Overview Local drug delivery – eliminates side effects of chemical castration and testosterone suppression<30-minute outpatient procedure using equipment for routine biopsyContinuous drug release for 2+ yearsHigh loading capacity of up to 80% drug in candidate formulationsAll components have a long track record of human safety Alessa Founder, Dr. Pamela Munster
- [Prostate Cancer](https://dev-alessa.pantheonsite.io/prostate-cancer/) - Prostate cancer is the most common male cancer Millions of men have must make a stark and suboptimal binary choice today: Do something aggressive early on — or surveil for years.Alessa offers an alternative: therapeutic surveillance. 0 % Thirteen percent of men will be diagnosed with prostate cancer in their lifetimes 0 An estimated 1.5
- [Pipeline](https://dev-alessa.pantheonsite.io/science/pipeline/) - Pipeline Program Payload Pre-Clinical Phase I Phase II/III NDA Filing Enolen® Low to Intermediate Risk Localized Prostate Cancer Payload: Enzalutamide Implant Pre-Clinical Phase I Phase II/III NDA Filing EP-001 Pre-prostatectomy PoC Pamolen™ Intermediate to High Risk Localized Prostate Cancer Payload: PARP Inhibitor Combinations Pre-Clinical Phase I Phase II/III NDA Filing IND 2H/26 Biolen® Benign Prostatic Hyperplasia (BPH) Payload:
- [Clinical Trials](https://dev-alessa.pantheonsite.io/clinical-trials/) - Clinical Trials Alessa is currently conducting several clinical studies of minimally-invasive, drug delivery implantable systems in patients with prostate cancer.Our systems are designed to administer anti-androgen drugs to the tumor in the prostate in a sustained manner without systemic exposure. Enolen A Study to Establish the Feasibility of Enolen for the Local Delivery of Enzalutamide
- [Careers](https://dev-alessa.pantheonsite.io/careers/) - Careers We have no open positions at this time. If you’d like to submit your info for future openings you can reach out to us using our contact form.
- [Contact](https://dev-alessa.pantheonsite.io/contact/) - Contact Us Alessa Therapeutics, Inc.930 Brittan AvenueSan Carlos, California 94070 First Name Last Name Email Message Send

## My Templates

- [view live site](https://dev-alessa.pantheonsite.io/?elementor_library=view-live-site) - Content area
- [Site Header](https://dev-alessa.pantheonsite.io/?elementor_library=elementor-header-128) - Content area
- [Default Kit](https://dev-alessa.pantheonsite.io/?elementor_library=default-kit)
- [Team Bio](https://dev-alessa.pantheonsite.io/?elementor_library=team-bio) - Team Bio Dr Munster is the Founder and Chief Scientific Advisor of Alessa. She is a physician-scientist and practicing oncologist with 30 years of experience in early drug development and translating research discoveries into clinical testing. She is the director of the Phase I program at UCSF and program leader for Molecular Oncology and Hereditary
- [pre-updates dec 16](https://dev-alessa.pantheonsite.io/?elementor_library=pre-updates-dec-16) - Science Alessa Drug Delivery System Overview Local drug delivery – eliminates side effects of chemical castration and testosterone suppression<30-minute outpatient procedure using equipment for routine biopsyContinuous drug release for 2+ yearsHigh loading capacity of up to 80% drug in candidate formulationsAll components have a long track record of human safety Alessa Founder, Dr. Pamela Munster
- [Pipeline Item](https://dev-alessa.pantheonsite.io/?elementor_library=pipeline-item) - Pipeline Item Pre-Clinical Phase I Phase II/III NDA Filing
- [Team Item](https://dev-alessa.pantheonsite.io/?elementor_library=team-item) - Team Item Read Bio
- [Site Footer](https://dev-alessa.pantheonsite.io/?elementor_library=elementor-footer-164) - Content area
- [News Archive](https://dev-alessa.pantheonsite.io/?elementor_library=elementor-archive-698) - Newsroom Latest Press Releases & News News Press Releases All Press Releases January 9, 2025 Alessa Therapeutics Announces First Patient Enrolled in the Enolen Study for Localized Drug Delivery for Prostate Cancer SAN CARLOS, CA (January 9, 2025) – Alessa Therapeutics, Inc., a privately held drug development company developing an innovative and proprietary localized drug delivery
- [contact-backup 12-11 del before launch](https://dev-alessa.pantheonsite.io/?elementor_library=contact-backup-12-11-del-before-launch) - Contact Us Alessa Therapeutics, Inc.930 Brittan AvenueSan Carlos, California 94070 First Name Last Name Email Message Send
- [Investor Item](https://dev-alessa.pantheonsite.io/?elementor_library=elementor-loop-item-299)
- [News Single](https://dev-alessa.pantheonsite.io/?elementor_library=elementor-single-post-763) - News Single News Single
- [Error 404](https://dev-alessa.pantheonsite.io/?elementor_library=elementor-error-404-60) - 404 The page can't be found. Homepage
- [News Item](https://dev-alessa.pantheonsite.io/?elementor_library=elementor-loop-item-95) - News Item Read More Read More

## Investors

- [Mission biolabs](https://dev-alessa.pantheonsite.io/investor/mission-biolabs/)
- [Johnson & Johnson](https://dev-alessa.pantheonsite.io/investor/johnson-johnson/)
- [Cure Ventures](https://dev-alessa.pantheonsite.io/investor/cure-ventures/)
- [UCSF](https://dev-alessa.pantheonsite.io/investor/ucsf/)

## Newsroom

- [Alessa Therapeutics Announces First Patient Enrolled in the Enolen Study for Localized Drug Delivery for Prostate Cancer](https://dev-alessa.pantheonsite.io/news/alessa-therapeutics-announces-first-patient-enrolled-in-the-enolen-study-for-localized-drug-delivery-for-prostate-cancer/) - SAN CARLOS, CA (January 9, 2025) – Alessa Therapeutics, Inc., a privately held drug development company developing an innovative and proprietary localized drug delivery technology for the treatment of prostate disease, announced the enrollment of the first patient in the company’s Enolen® clinical study at the National Cancer Institute (NCI), part of the National Institutes of
- [Alessa Therapeutics Appoints Cam Gallagher as President & Chief Executive Officer](https://dev-alessa.pantheonsite.io/news/alessa-therapeutics-appoints-cam-gallagher-as-president-chief-executive-officer/) - SAN CARLOS, CA (December 16, 2024) – Alessa Therapeutics, a clinical-stage drug development company pioneering an innovative and proprietary localized drug delivery technology for the early treatment of prostate cancer and other diseases, announced today the appointment of Cam Gallagher as President and Chief Executive Officer, effective immediately. Mr. Gallagher, a seasoned leader and serial entrepreneur
- [Alessa Therapeutics Announces Closing $15M Seed Financing](https://dev-alessa.pantheonsite.io/news/alessa-therapeutics-announces-closing-15m-seed-financing/) - SAN CARLOS, CA (December 12, 2024) – Alessa Therapeutics, Inc., a clinical-stage drug development company pioneering an innovative and proprietary localized drug delivery technology for the early interception of cancer and other diseases, announced the closing of a $15M seed financing led by Mission BioCapital joined by Johnson & Johnson (through its corporate venture capital organization,
- [Alessa Therapeutics Announces Podium Presentation at the 2024 AUA Meeting](https://dev-alessa.pantheonsite.io/news/alessa-therapeutics-announces-podium-presentation-at-the-2024-aua-meeting/) - San Carlos, Calif., April 22,2024 – Alessa Therapeutics Inc. today announced that they will be presenting a podium poster at the 2024 annual American Association of Urology (AUA) annual meeting in San Antonio, TX. Poster Title: A Phase 1 Safety, PK and Preliminary Efficacy Study of Localized Therapy using Biolen (Bicalutamide) Implants for Early-Stage Prostate CancerSession
- [Alessa Therapeutics Announces Poster Presentation at the 2024 EAU Meeting](https://dev-alessa.pantheonsite.io/news/alessa-therapeutics-announces-poster-presentation-at-the-2024-eau-meeting-2/) - San Carlos, Calif., March 26,2024 – Alessa Therapeutics Inc. today announced that they will be presenting a poster at the 2024 annual European Association of Urology (EAU) annual meeting in Paris, FR. Poster Title: A Phase 1 Safety, PK and Preliminary Efficacy Study of Localized Therapy using Biolen (Bicalutamide) Implants for Early-Stage Prostate CancerSession Date and
- [Alessa Therapeutics Announces Poster Presentation at the 2024 EAU Meeting](https://dev-alessa.pantheonsite.io/news/alessa-therapeutics-announces-poster-presentation-at-the-2024-eau-meeting/) - San Carlos, Calif., March 26,2024 – Alessa Therapeutics Inc. today announced that they will be presenting a poster at the 2024 annual European Association of Urology (EAU) annual meeting in Paris, FR. Poster Title: A Phase 1 Safety, PK and Preliminary Efficacy Study of Localized Therapy using Biolen (Bicalutamide) Implants for Early-Stage Prostate CancerSession Date and
- [Alessa Therapeutics Announces First Patient Enrollment in Biolen®+RT Study with National Cancer Institute](https://dev-alessa.pantheonsite.io/news/alessa-therapeutics-announces-first-patient-enrollment-in-biolenrt-study-with-national-cancer-institute/) - SAN CARLOS, CALIFORNIA, US, February 23, 2022 /EINPresswire.com/ Alessa Therapeutics, Inc., a clinical-stage drug development company developing an innovative and proprietary localized drug delivery technology to treat prostate disease, announced the enrollment of the first two men with prostate cancer in the company’s Biolen+RT clinical study. Biolen+RT (NCT 04943536) is a Phase 1 clinical
- [Alessa Therapeutics Announces Research Collaboration with Janssen](https://dev-alessa.pantheonsite.io/news/alessa-therapeutics-announces-research-collaboration-with-janssen/) - SAN CARLOS, CALIFORNIA, US, October 11, 2021 /EINPresswire.com/ Alessa Therapeutics, Inc., a clinical-stage drug development company developing implantable drug delivery systems focused on sustained delivery of drugs to solid organ tumors, announced that it has entered into a research collaboration agreement with an affiliate of Janssen Research & Development, LLC. This agreement was facilitated by Johnson
- [Alessa Therapeutics Announces IND Clearance for a Study in Collaboration with the National Cancer Institute](https://dev-alessa.pantheonsite.io/news/alessa-therapeutics-announces-ind-clearance-for-a-study-in-collaboration-with-the-national-cancer-institute/) - SAN CARLOS, CALIFORNIA, US, June 7, 2021 /EINPresswire.com/ Alessa Therapeutics, Inc., a clinical-stage drug development company developing an innovative and proprietary localized drug delivery technology for the treatment of prostate disease, announced that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug application (IND) for Biolen®. Alessa, in collaboration with
- [Alessa Therapeutics Announces First Patient Enrolled in Biolen-PC Study for Localized Drug Delivery for Prostate Cancer](https://dev-alessa.pantheonsite.io/news/alessa-therapeutics-announces-first-patient-enrolled-in-biolen-pc-study-for-localized-drug-delivery-for-prostate-cancer/) - SAN CARLOS, CALIFORNIA, US, October 13, 2020 /EINPresswire.com/ Alessa Therapeutics, Inc., a privately held drug development company developing an innovative and proprietary localized drug delivery technology for the treatment of prostate disease, announced the enrollment of the first patient in the company’s Biolen-PC clinical study. Biolen-PC is a first-in-man study evaluating safety and patient
- [Alessa Therapeutics Announces First Australian Patient Enrolled in Biolen-PC Study for Localized Drug Delivery for Prostate Cancer](https://dev-alessa.pantheonsite.io/news/alessa-therapeutics-announces-first-australian-patient-enrolled-in-biolen-pc-study-for-localized-drug-delivery-for-prostate-cancer/) - SAN CARLOS, CALIFORNIA, US, March 17, 2020 /EINPresswire.com/ Alessa Therapeutics, Inc., a privately held drug development company developing an innovative and proprietary localized drug delivery technology for the treatment of prostate disease, announced the enrollment of the first patient in the company’s Biolen-PC clinical study in Australia. Biolen-PC (NCT 04284761) is a first-in-man study
- [World-First Prostate Cancer Treatment Trialed In Tauranga](https://dev-alessa.pantheonsite.io/news/world-first-prostate-cancer-treatment-trialed-in-tauranga/) - New Zealand’s lack of COVID-19 cases saw a world-first prostate cancer surgery taking place in Tauranga. Jim Boltman, 64, says his whole life is “back to normal” after undergoing the new surgery at Tauranga Hospital on October 8. The 64-year-old was diagnosed with prostate cancer after realising he had a problem when he was constantly
- [Alessa Therapeutics is a 2020 Leadership Forum and HealthTech Showcase Finalist](https://dev-alessa.pantheonsite.io/news/alessa-therapeutics-is-a-2020-leadership-forum-and-healthtech-showcase-finalist/) - The American Diabetes Association’s Leaders Forum HealthTech Showcase hosts over 400 Bay Area biotech, venture capital and investment banking executives. Alessa Therapeutics is proud to be a 2020 finalist in the HealthTech Showcase, which features start-up ventures in the life science and digital health arenas.

## Pipeline Items

- [Pamolen™](https://dev-alessa.pantheonsite.io/blog/pipeline-item/pamolen/)
- [Biolen®](https://dev-alessa.pantheonsite.io/blog/pipeline-item/biolen/)
- [Enolen®](https://dev-alessa.pantheonsite.io/blog/pipeline-item/enolen/)

## Team Members

- [Maithili Rairkar, PhD](https://dev-alessa.pantheonsite.io/team/maithili-rairkar-phd/) - Dr. Rairkar has over 22 years of experience leading drug–device combination development from concept to regulatory approval. She has held senior CMC roles at Antiva Biosciences, Chrono Therapeutics, Incline Therapeutics (acquired by The Medicines Company), Alza (a Johnson & Johnson company), and Discovery Laboratories, driving innovation and operational excellence across every stage of development.
- [Zach Collins, PhD](https://dev-alessa.pantheonsite.io/team/zach-collins-phd/) - Dr. Collins leads business development and strategic planning at Alessa. At Mission BioCapital, Zach has managed over a dozen investments and served in several interim executive roles across therapeutic areas. Prominent investments Zach led or supported include SiteOne Therapeutics (acquired by Eli Lilly), Vedere Bio (acquired by Novartis), and Nuvig Therapeutics.
- [Annie Mitsak](https://dev-alessa.pantheonsite.io/team/annie-mitsak/)
- [Richard Lim](https://dev-alessa.pantheonsite.io/team/richard-lim/)
- [May Han, PhD](https://dev-alessa.pantheonsite.io/team/may-han-phd/)
- [Cam Gallagher](https://dev-alessa.pantheonsite.io/team/cam-gallagher/) - Mr. Gallagher has over 33 years of experience as a biotech executive and serial entrepreneur. He was previously Co-Founder, President & Board Member at Zentalis Pharmaceuticals. He also co-founded Zavante and Ray Therapeutics. He currently serves as board member of Opus Genetics (Chair), Crosslink Therapeutics (Chair) and SelectION.. He previously served on the boards of
- [Bonnie Wettersten](https://dev-alessa.pantheonsite.io/team/bonnie-wettersten/) - Bonnie Wettersten has over 20 years of experience offering strategic direction and coordination of global clinical operations in oncology. Prior to joining the Alessa Team, Bonnie was the Global Clinical Operations Head at OSIPharmaceuticals (acquired by Astellas Pharmaceuticals), GlaxoSmithKline (Therapy Area Head), and Aventis Pharma (acquired by Sanofi).
- [Pamela Munster, MD](https://dev-alessa.pantheonsite.io/team/pamela-munster-md/) - Dr Munster is the Founder and Chief Scientific Advisor of Alessa. She is a physician-scientist and practicing oncologist with 30 years of experience in early drug development and translating research discoveries into clinical testing. She is the director of the Phase I program at UCSF and program leader for Molecular Oncology and Hereditary Cancer. She
- [Steve Tregay, PhD](https://dev-alessa.pantheonsite.io/team/steve-tregay-phd/)
- [Doug Crawford, PhD](https://dev-alessa.pantheonsite.io/team/doug-crawford-phd/)